RPA-LF Assay Evaluated for Cutaneous Leishmaniasis in Colombia
|
By LabMedica International staff writers Posted on 17 May 2021 |

Image: Results of the Recombinase Polymerase Amplification-Lateral Flow (RPA-LF) assay for cutaneous leishmaniasis (Photo courtesy of University of Texas Medical Branch)
Cutaneous leishmaniasis (CL) is a recognized public health challenge in the Americas, with an average of 55,000 cases per year between 2001 and 2018 in 17 countries of the region. Most cases (79.4%) have been acquired in and continue to occur in rural areas.
Currently available diagnostic methods for CL have several limitations. Light microscopic analysis of smears obtained from cutaneous lesions is the most commonly used diagnostic method for CL because of its low cost, yet its sensitivity varies widely depending on the experience and skill of the operator. In addition, sensitivity of microscopy is diminished in lesions of longer duration in chronic lesions with their notorious low parasite burden.
A team of tropical medicine specialists from the University of Texas Medical Branch (Galveston, TX, USA) and the Universidad Icesi (Cali, Colombia) conducted a cross-sectional study of diagnostic test performance between January 2018 and July 2019. There were 118 participants ≥2 years of age, with ulcerated skin lesions of more than two weeks’ duration were eligible and enrolled consecutively either in their residence (in rural Tumaco) by community health workers, or when seeking care at the primary health facility in urban Tumaco or the reference center laboratory in Cali.
The team utilized a composite “gold standard” based on microscopy of lesion smear, culture, histopathology of biopsy and qPCR18S as a reference. Minimally invasive swab and FTA filter paper samples were obtained by community health workers and highly trained technicians from ulcerated lesions. The investigators evaluated the diagnostic test performance of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, coupled with a lateral flow (LF) immunochromatographic strip, in a field setting and a laboratory reference center.
The scientists reported that the sensitivity and specificity of RPA-LF in the reference lab scenario were 87% (95%CI 74–94) and 86% (95%CI 74–97), respectively. In the field scenario, the sensitivity was 75% (95%CI 65–84) and specificity 89% (95%CI 78–99). Positive likelihood ratios in both scenarios were higher than six while negative likelihood ratios ranged to 0.2–0.3 supporting the usefulness of RPA-LF to rule-in and potentially to rule-out infection.
The authors concluded that RPA-LF is a valid, efficacious test to diagnose CL that could replace or complement microscopy in rural areas. Its combination with non-invasive sampling and low complexity requirements for processing and interpreting results position this test as an achievable alternative for diagnosis of CL at points of care in Colombia. The study was published on April 28, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Texas Medical Branch
Universidad Icesi
Currently available diagnostic methods for CL have several limitations. Light microscopic analysis of smears obtained from cutaneous lesions is the most commonly used diagnostic method for CL because of its low cost, yet its sensitivity varies widely depending on the experience and skill of the operator. In addition, sensitivity of microscopy is diminished in lesions of longer duration in chronic lesions with their notorious low parasite burden.
A team of tropical medicine specialists from the University of Texas Medical Branch (Galveston, TX, USA) and the Universidad Icesi (Cali, Colombia) conducted a cross-sectional study of diagnostic test performance between January 2018 and July 2019. There were 118 participants ≥2 years of age, with ulcerated skin lesions of more than two weeks’ duration were eligible and enrolled consecutively either in their residence (in rural Tumaco) by community health workers, or when seeking care at the primary health facility in urban Tumaco or the reference center laboratory in Cali.
The team utilized a composite “gold standard” based on microscopy of lesion smear, culture, histopathology of biopsy and qPCR18S as a reference. Minimally invasive swab and FTA filter paper samples were obtained by community health workers and highly trained technicians from ulcerated lesions. The investigators evaluated the diagnostic test performance of Isothermal Recombinase Polymerase Amplification (RPA) targeting Leishmania kinetoplast DNA, coupled with a lateral flow (LF) immunochromatographic strip, in a field setting and a laboratory reference center.
The scientists reported that the sensitivity and specificity of RPA-LF in the reference lab scenario were 87% (95%CI 74–94) and 86% (95%CI 74–97), respectively. In the field scenario, the sensitivity was 75% (95%CI 65–84) and specificity 89% (95%CI 78–99). Positive likelihood ratios in both scenarios were higher than six while negative likelihood ratios ranged to 0.2–0.3 supporting the usefulness of RPA-LF to rule-in and potentially to rule-out infection.
The authors concluded that RPA-LF is a valid, efficacious test to diagnose CL that could replace or complement microscopy in rural areas. Its combination with non-invasive sampling and low complexity requirements for processing and interpreting results position this test as an achievable alternative for diagnosis of CL at points of care in Colombia. The study was published on April 28, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
University of Texas Medical Branch
Universidad Icesi
Latest Microbiology News
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
- CE-Marked Blood Assay Automates Tuberculosis Infection Testing
- Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more




 Assay.jpg)



